Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study | Zendy

Giuseppe Colucci | Zendy; Roberto Labianca | Zendy; Francesco Di Costanzo | Zendy; Vittorio Gebbia | Zendy; Giacomo Cartenì | Zendy; B. Massidda | Zendy; E. Dapretto | Zendy; Luigi Manzione | Zendy; Elena Piazza | Zendy; Mirella Sannicolò | Zendy; Marco Ciaparrone | Zendy; Luigi Cavanna | Zendy; Francesco Giuliani | Zendy; Evaristo Maiello | Zendy; Antonio Testa | Zendy; Paolo Pederzoli | Zendy; Massimo Falconi | Zendy; Ciro Gallo | Zendy; Massimo Di Maïo | Zendy; Francesco Perrone | Zendy

Open Access

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Author(s) -

Giuseppe Colucci,

Roberto Labianca,

Francesco Di Costanzo,

Vittorio Gebbia,

Giacomo Cartenì,

B. Massidda,

E. Dapretto,

Luigi Manzione,

Elena Piazza,

Mirella Sannicolò,

Marco Ciaparrone,

Luigi Cavanna,

Francesco Giuliani,

Evaristo Maiello,

Antonio Testa,

Paolo Pederzoli,

Massimo Falconi,

Ciro Gallo,

Massimo Di Maïo,

Francesco Perrone

Publication year - 2010

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2009.25.4433

Subject(s) - gemcitabine , medicine , pancreatic cancer , hazard ratio , clinical endpoint , cisplatin , antimetabolite , gastroenterology , chemotherapy , performance status , randomized controlled trial , surgery , cancer , confidence interval

Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo Italiano Pancreas 1 randomized phase III trial aimed to compare gemcitabine plus cisplatin versus gemcitabine alone (ClinicalTrials.gov ID NCT00813696).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research